Stories

Industry isn't fearing Trump's drug price speech

Traders work on the floor of the New York Stock Exchange.
Drug company stocks haven't wavered much. Photo: Bryan R. Smith/AFP via Getty Images

Even though the Trump administration is playing up the president's prescription drug speech today, few people believe the rhetoric and policies will lead to substantial changes, and some of the bolder ideas may never come to pass.

What we're hearing: "The President's bark will be worse than his bite as he blames all parties within the drug supply distribution chain, including drug manufacturers, insurers, PBMs, distributors and hospitals, for high drug costs,” Andrea Harris of Height Capital Markets said in a note to investors.

More stories loading.